Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: Results of the ACTG 5283 study
Amneris E. Luque*, Susan E. Cohn, Jeong Gun Park, Yoninah Cramer, Adriana Weinberg, Elizabeth Livingston, Karin L. Klingman, Francesca Aweeka, D. Heather Watts
Dive into the research topics of 'Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: Results of the ACTG 5283 study'. Together they form a unique fingerprint.